Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis

Completed

Conditions: Psoriasis

First Posted Date: 2004-12-06

Last Posted Date: 2006-08-31

Lead Sponsor: Novartis

Registration Number: NCT00098189

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

Phase 3

Completed

Conditions: Chickenpox
Herpes Zoster

First Posted Date: 2004-12-03

Last Posted Date: 2007-09-26

Lead Sponsor: Novartis

Target Recruit Count: 76

Registration Number: NCT00098046

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇵🇦
Novartis Investigational Site, David, Chiriqui, Panama

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

Phase 2

Completed

Conditions: Primary Insulin Hypersecretion
Obesity

First Posted Date: 2004-10-15

Last Posted Date: 2009-09-22

Lead Sponsor: Novartis

Target Recruit Count: 160

Registration Number: NCT00094146

Locations: 🇺🇸
New Orleans Center for Clinical Research, New Orleans, Louisiana, United States
🇺🇸
University of Tennessee, Memphis, Tennessee, United States
🇺🇸
University of Wisconsin Beers-Murphy Clinical Nutrition Clinic, Madison, Wisconsin, United States

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Phase 3

Completed

Conditions: Hypercalcemia of Malignancy
Lung Cancer
Metastatic Cancer
Pain
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-07-22

Last Posted Date: 2013-02-21

Lead Sponsor: Novartis

Target Recruit Count: 600

Registration Number: NCT00003884

Locations: 🇺🇸
SORRA Research Center, Birmingham, Alabama, United States
🇺🇸
Brookwood ACCC, Birmingham, Alabama, United States
🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 52 locations

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2004-05-26

Last Posted Date: 2013-01-03

Lead Sponsor: Novartis

Registration Number: NCT00006343

Locations: 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Phase 3

Terminated

Conditions: Colorectal Cancer
Diarrhea

First Posted Date: 2004-05-24

Last Posted Date: 2012-05-25

Lead Sponsor: Novartis

Target Recruit Count: 89

Registration Number: NCT00006269

Locations: 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
🇺🇸
Theradex, Princeton, New Jersey, United States

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-05-04

Last Posted Date: 2013-01-18

Lead Sponsor: Novartis

Registration Number: NCT00006053

Locations: 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-04-26

Last Posted Date: 2013-02-21

Lead Sponsor: Novartis

Registration Number: NCT00006475

Locations: 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-04-02

Last Posted Date: 2014-01-31

Lead Sponsor: Novartis

Registration Number: NCT00006052

Locations: 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

First Posted Date: 2003-11-13

Last Posted Date: 2013-02-21

Lead Sponsor: Novartis

Registration Number: NCT00014638

Locations: 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
Long Beach Memorial Breast Center, Long Beach, California, United States
🇺🇸
Cancer Research Network, Inc., Hollywood, Florida, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy